首页> 美国卫生研究院文献>Cancer Medicine >Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process–A systematic review
【2h】

Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process–A systematic review

机译:晚期皮肤黑色素瘤的新型癌症治疗方法:放射学在决策过程中的附加价值-系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Advanced malignant melanoma represents a public health matter due to its rising incidence and aggressiveness. Novel therapies such as immunotherapy are showing promising results with improved progression free and overall survival in melanoma patients. However, novel targeted and immunotherapies could generate atypical patterns of response which are nowadays a big challenge since imaging criteria (ie Recist 1.1) have not been proven to be always reliable to assess response. Radiomics and in particular texture analysis (TA) represent new quantitative methodologies which could reduce the impact of these limitations providing most robust data in support of clinical decision process. The aim of this paper was to review the state of the art of radiomics/TA when it is applied to the imaging of metastatic melanoma patients.
机译:晚期恶性黑色素瘤由于其发病率和侵略性上升而代表着公共卫生问题。诸如免疫疗法之类的新疗法在黑素瘤患者中显示出令人鼓舞的结果,具有无进展的进展和总体生存的改善。然而,新型的靶向和免疫疗法可能会产生非典型的反应模式,这是当今的一大挑战,因为尚未证明成像标准(即Recist 1.1)始终能够可靠地评估反应。放射学,尤其是质地分析(TA)代表了新的定量方法,可以减少这些局限性的影响,从而提供最可靠的数据来支持临床决策过程。本文的目的是回顾放射线学/ TA技术在转移性黑色素瘤患者成像中的应用现状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号